Dr. David G. Telander, M.D., PH.D
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,672
Licensed in California since 2003, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Minnesota Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
CA license A82894 (first issued 2003; current) -
Ophthalmology Physician
CA license A82894 (first issued 2003; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mercy General Hospital Sacramento, CA
Medical groups
- Vitreo-Retinal Medical Group, Inc. (22 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,672
- Services billed
- 69,193
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 25,740 | 122 |
| Imaging of retina | 3,706 | 1,618 |
| Injection, aflibercept, 1 mg | 2,522 | 351 |
| Established patient complete exam of visual system | 2,339 | 1,337 |
| Injection of drug into eye | 1,855 | 556 |
| Injection, ranibizumab, 0.1 mg | 1,321 | 88 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 345 | 329 |
| New patient complete exam of visual system | 213 | 213 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 175 | 14 |
| Extended exam of the back part of the eye with retinal drawing | 123 | 117 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Sacramento, CA | 273 |
| Dorzolamide Hcl Other prescribers in Sacramento, CA | 137 |
| Ofloxacin Other prescribers in Sacramento, CA | 110 |
| Ketorolac Tromethamine Other prescribers in Sacramento, CA | 49 |
| Brimonidine Tartrate Other prescribers in Sacramento, CA | 35 |
| Timolol Maleate Other prescribers in Sacramento, CA | 34 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Sacramento, CA | 33 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Sacramento, CA | 25 |
| Acetazolamide Other prescribers in Sacramento, CA | 23 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in Sacramento, CA | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 34 payments worth $1,901 in total to this clinician.
| AbbVie Inc. | $544 |
|---|---|
| Apellis Pharmaceuticals, Inc. | $278 |
| Mallinckrodt Hospital Products Inc. | $220 |
| Amgen Inc. | $165 |
| Genentech, Inc. | $158 |
| Astellas Pharma US Inc | $142 |
| Harrow Eye, LLC | $103 |
| Regeneron Healthcare Solutions, Inc. | $80.26 |
| Food and Beverage | $1,358 |
|---|---|
| Consulting Fee | $544 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jan 30, 2025 | Consulting Fee OZURDEX · EYE CARE | $544 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $144,353 in research payments for these studies, mostly to the institutions running them.
- Phase IIa Geographic Atrophy Study
Genentech, Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc. - NRICH
Notal Vision, Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc. · Enrolling by invitation · NCT03999801
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.